An alternative marker of low-density lipoprotein cholesterol in coronary artery disease: non-high-density lipoprotein cholesterol

Müjgan ERCAN, Esra OĞUZ, Fatma Meriç YILMAZ, Nihal BOĞDAYCIOĞLU, Kübranur ÜNAL, Deniz ŞAHİN, Sema UYSAL
334 205


Dyslipidemia is one of the most important risk factors for coronary artery disease (CAD), and low-density lipoprotein cholesterol (LDL-C) is used to measure dyslipidemia. Non-high-density lipoprotein cholesterol (non-HDL-C) seems to be an alternative parameter to LDL-C as it is not influenced by triglyceride (TG) levels. The aim of this study is to compare non-HDL-C and LDL-C levels as risk markers in CAD patients. Materials and methods: One hundred and ten CAD patients and 42 individuals with normal coronary angiography results were included in this study. Patients were divided into 2 groups: TG < 200 mg/dL (n = 75) as group 1 and TG > 200 mg/dL (n = 35) as group 2. Total cholesterol (TC), TG, and HDL-C levels were analyzed with a Roche Modular P800 autoanalyzer. LDL-C and non-HDL-C levels were calculated. Results: There were statistically significant differences in TC, TG, HDL-C, and non-HDL-C levels when the groups were compared. Non-HDL-C levels of group 2 were statistically higher than those of group 1 and the control group. There was no significant difference in LDL-C levels between the groups. Conclusion: Non-HDL-C levels are better risk markers than LDL-C levels, especially in patients with TG > 200 mg/dL, and non-HDL-C levels should be taken into consideration when evaluating the risk of CAD.


Non-high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, coronary artery disease

Full Text:



Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007; 58: 513–522.

Carl A. Burtis ERA, David E. Bruns, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Salt Lake City, UT, USA: Elsevier Health Sciences; 2005.

Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population- based prospective studies. J Cardiovasc Risk 1996; 3: 213–219.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413–1419.

Farwell WR, Sesso HD, Buring JE, Gaziano JM. Non-high- density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol 2005; 96: 1129–1134.

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006; 98: 1363–1368.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D’Agostino RB et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776–785.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

Sigdel M, Yadav BK, Gyawali P, Regmi P, Baral S, Regmi SR, Jha B. Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction. BMC Res Notes 2012; 5: 640.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002–3009.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375–3383.

Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. European Heart J 1998; 19: 2–11.

Ravi GR, Pradeepa R, Mohan V. Hypertriglyceridemia and coronary artery disease -- an update. Indian Heart J 2004; 56: 21–26.

Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18–25.

Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dL. Am J Cardiol 2006; 98: 1599–1602.

Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PW, D’Agostino RB. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007; 1: 583–592.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811–822.

Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81: 26–31.

Gökçel A, Baltalı M, Gümürdülü Y, Özşahin AK, Güvener N, Tütüncü NB. Yüksek dansiteli lipoprotein dışı kolesterolün klinik kullanımı. Turkiye Klinikleri J Cardiol 2002; 15: 165– 169 (in Turkish).

Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J, Schillinger M, Huber K, Maurer G, Wiesbauer F. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age). Eur J. Clin Invest 2012; 42: 631–636.

Garg PR, Kabita S, Sinha E, Kalla L, Kaur L, Saraswathy KN. The association of non-HDL cholesterol with the presence of metabolic syndrome in North Indian subjects with and without CAD. Ann Hum Biol 2013; 40: 111–115.

Uçar B, Kılıç Z, Dinleyici EÇ, Çolak Ö, Güneş E. Serum lipid profiles including non-high density lipoprotein cholesterol levels in Turkish school-children. Anadolu Kardiyol Derg 2007; 7: 415–420.